196 related articles for article (PubMed ID: 37894390)
1. MicroRNAs in Prostate Cancer: Implications for Treatment Response and Therapeutic Targets.
Hussein MA; Munirathinam G
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894390
[TBL] [Abstract][Full Text] [Related]
2. Role of microRNAs in the development, prognosis and therapeutic response of patients with prostate cancer.
Ghafouri-Fard S; Shoorei H; Taheri M
Gene; 2020 Oct; 759():144995. PubMed ID: 32721477
[TBL] [Abstract][Full Text] [Related]
3. microRNAs as pharmacological targets in cancer.
Soriano A; Jubierre L; Almazán-Moga A; Molist C; Roma J; de Toledo JS; Gallego S; Segura MF
Pharmacol Res; 2013 Sep; 75():3-14. PubMed ID: 23537752
[TBL] [Abstract][Full Text] [Related]
4. Towards the definition of prostate cancer-related microRNAs: where are we now?
Gandellini P; Folini M; Zaffaroni N
Trends Mol Med; 2009 Sep; 15(9):381-90. PubMed ID: 19716766
[TBL] [Abstract][Full Text] [Related]
5. The miRNAs involved in prostate cancer chemotherapy response as chemoresistance and chemosensitivity predictors.
Konoshenko M; Laktionov P
Andrology; 2022 Jan; 10(1):51-71. PubMed ID: 34333834
[TBL] [Abstract][Full Text] [Related]
6. Non-coding RNAs in Prostate Cancer: From Discovery to Clinical Applications.
Ceder Y
Adv Exp Med Biol; 2016; 886():155-170. PubMed ID: 26659491
[TBL] [Abstract][Full Text] [Related]
7. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer.
Xu M; Evans L; Bizzaro CL; Quaglia F; Verrillo CE; Li L; Stieglmaier J; Schiewer MJ; Languino LR; Kelly WK
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011027
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targets.
Fenderico N; Casamichele A; Profumo V; Zaffaroni N; Gandellini P
Curr Med Chem; 2013; 20(12):1566-84. PubMed ID: 23410173
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs Role in Prostate Cancer.
Balacescu O; Dumitrescu RG; Marian C
Methods Mol Biol; 2018; 1856():103-117. PubMed ID: 30178248
[TBL] [Abstract][Full Text] [Related]
12. CaP CURE Initiatives and Projects.
Soule HR
Rev Urol; 2003; 5 Suppl 2(Suppl 2):S60-5. PubMed ID: 16986049
[TBL] [Abstract][Full Text] [Related]
13. CaP CURE Initiatives and Projects.
Soule HR
Rev Urol; 2003; 5 Suppl 3(Suppl 3):S92-7. PubMed ID: 16985957
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of microRNAs in prostate cancer: implications for personalized medicine.
Gandellini P; Folini M; Zaffaroni N
Discov Med; 2010 Mar; 9(46):212-8. PubMed ID: 20350487
[TBL] [Abstract][Full Text] [Related]
15. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
16. Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.
Lee TJ; Yuan X; Kerr K; Yoo JY; Kim DH; Kaur B; Eltzschig HK
Pharmacol Rev; 2020 Jul; 72(3):639-667. PubMed ID: 32554488
[TBL] [Abstract][Full Text] [Related]
17. Identification of microRNA signature and potential pathway targets in prostate cancer.
Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB
Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835
[TBL] [Abstract][Full Text] [Related]
18. A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer.
Daniel R; Wu Q; Williams V; Clark G; Guruli G; Zehner Z
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28621736
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer.
Tang S; Li S; Liu T; He Y; Hu H; Zhu Y; Tang S; Zhou H
Cancer Lett; 2021 Apr; 502():71-83. PubMed ID: 33453304
[TBL] [Abstract][Full Text] [Related]
20. Targeting MicroRNAs in Prostate Cancer Radiotherapy.
Ni J; Bucci J; Chang L; Malouf D; Graham P; Li Y
Theranostics; 2017; 7(13):3243-3259. PubMed ID: 28900507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
